Пошук по сайту
Авторизація
Логин:
Пароль:
Регистрация
Забыли свой пароль?
Періодика
Медична інформатика та інженерія
Партнери
Поиск информации по диагнозу / Med And Me Первый украинский нефрологический сайт проф. Д. Иванова Zepter
Технічна підтримка

Американський ринок терапії нетримання сечі мінімально інвазивним методом (U.S. Minimally Invasive Urinary Incontinence Therapy Systems Market)



Incontinence may be defined as the involuntary loss of bladder or bowel control. In the United States (U.S.), urinary incontinence (UI) afflicts an estimated 50 million people. According to the National Association for Continence (NAFC), approximately 75% to 80% of the UI populations are women, with 9 million to 13 million suffering severe symptoms.

Although UI is an extremely common problem, and has a significant impact on quality of life, the vast majority of those who experience the condition do not undergo treatment, in part due to cost, embarrassment, or fear of risky surgical procedures. There is therefore a very strong demand for less costly, less invasive and more tolerable, discreet, nonsurgical UI therapies.

While current economic conditions and other factors continue to restrain market growth, the market for minimally invasive UI therapy systems is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $190 million in 2010, the U.S. Minimally Invasive Urinary Incontinence Therapy Systems market is expected to increase at a healthy compound annual rate of 2.7%, with sales reaching more than $220 million in 2015. The market is expected to benefit not only from strong demand but from highly positive demographic trends, including a large, growing UI population and limited options for truly effective therapeutic alternatives.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include injectable urethral bulking agents; urethral sling systems; implantable sacral nerve neurostimulators; nonsurgical office-based neuromodulation/percutaneous tibial nerve stimulation; and other nonsurgical treatments.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i. Types of Urinary Incontinence
ii. Stress Urinary Incontinence
iii. Overactive Bladder and Urge Incontinence
iv. Treatment

a. Prescription Drug Therapy
b. Botulinum Toxin
c. Bulking Agents
d. Implantable Neurostimulation
e. Percutaneous Tibial Nerve Stimulation
f. Urethral Slings
g. Surgical Options

v. Minimally Invasive Urinary Incontinence Therapy Systems Market

a. Procedure Volumes
b. Market Forecast

vi. Methodology

Exhibit ES-1: Minimally Invasive Urinary Incontinence Therapy, Procedure Volumes Forecast, 2010-2015
Exhibit ES-2: Minimally Invasive Urinary Incontinence Therapy Systems, Market Forecast, 2010-2015

1. CLINICAL OVERVIEW OF URINARY INCONTINENCE

1.1 Anatomy of the Urinary System
1.2 Types of Urinary Incontinence
1.2.1 Stress Urinary Incontinence
1.2.1.1 Causes
1.2.2 Overactive Bladder and Urge Incontinence
1.2.2.1 Causes
1.3 Treatment
1.3.1 Prescription Drug Therapy
1.3.2 Botulinum Toxin
1.3.3 Bulking Agents
1.3.4 Sacral Nerve Stimulation
1.3.4.1 Implantable Neurostimulation
1.3.4.2 Percutaneous Tibial Nerve Stimulation
1.3.5 Urethral Slings
1.3.6 Surgical Options
Exhibit 1-1: Urinary Voiding and Afferent Signaling
Exhibit 1-2: Sacral Neuromodulation with an Implanted Electrical Stimulator

2. MINIMALLY INVASIVE URETHRAL BULKING AGENTS

2.1 Selected Products
2.1.1 Contigen
2.1.2 Coaptite
2.1.3 Durasphere EXP
2.1.4 Macroplastique
2.1.5 Bulkamid
2.2 Market Analysis
2.2.1 Procedure Volumes
2.2.2 Market Forecast
2.2.3 Competitive Analysis
Exhibit 2-1: The Coaptite Injectable Implant Procedure
Exhibit 2-2: The Macroplastique Urethral Bulking Agent
Exhibit 2-3: Macroplastique Treatment, Key Efficacy Results at 12 Months
Exhibit 2-4: Macroplastique Treatment, Key Adverse Events
Exhibit 2-5: Minimally Invasive Urethral Bulking Agent Therapy, Procedure Volumes Forecast, 2010-2015
Exhibit 2-6: Minimally Invasive Urethral Bulking Agents, Market Forecast, 2010-2015
Exhibit 2-7: 2010, Minimally Invasive Urethral Bulking Agents Market, Share by Supplier

3. MINIMALLY INVASIVE URETHRAL SLING SYSTEMS

3.1 Selected Products
3.1.1 American Medical Systems/Endo Pharmaceuticals
3.1.1.1 Urethral Slings for Women
3.1.1.2 Urethral Slings for Men
3.1.2 Bard Medical/C.R. Bard
3.1.3 Boston Scientific
3.1.4 Caldera Medical
3.1.5 Coloplast
3.1.6 Cook Medical/Cook Group
3.1.7 Ethicon/Johnson & Johnson
3.1.8 Promedon
3.2 Market Analysis
3.2.1 Procedure Volumes
3.2.2 Market Forecast
3.2.3 Competitive Analysis
Exhibit 3-1: 2011, Selected Urethral Sling Systems
Exhibit 3-2: The MiniArc Precise Single-Incision Sling System
Exhibit 3-3: The MiniArc Single-Incision Sling
Exhibit 3-4: The Monarc Subfascial Hammock
Exhibit 3-5: Suprapubic and Transobturator Approaches to Mid-Urethral SlingPlacement Using the BioArc SP and BioArc TO Sling Systems
Exhibit 3-6: 12-Step Mid-Urethral Sling Implant Procedure Using theBioArc SP Sling System
Exhibit 3-7: The In-Fast Ultra Transvaginal Sling
Exhibit 3-8: The Ajust Adjustable Single-Incision Sling
Exhibit 3-9: The Align Urethral Support System
Exhibit 3-10: The PelviLace Biourethral Support System
Exhibit 3-11: The Advantage Fit System
Exhibit 3-12: Components of the Advantage Transvaginal Mid-Urethral Sling System
Exhibit 3-13: Steps in a Mid-Urethral Sling Implant Procedure Using the Advantage Sling System
Exhibit 3-14: The Desara Sling System
Exhibit 3-15: Mesh Integrity, Comparison of the Desara Mesh with Other Slings
Exhibit 3-16: The Aris Transobturator Sling System
Exhibit 3-17: The Biodesign Tension-Free Urethral Sling
Exhibit 3-18: The TVT ABBREVO Continence System
Exhibit 3-19: Safety Advantages of the TVT ABBREVO Procedure
Exhibit 3-20: Comparable Clinical Improvement at 12 months, Modified TVTObturator System versus the Unaltered TVT Obturator System
Exhibit 3-21: TVT Tension-Free Support for Incontinence and TVT EXACT Continence Systems, Comparative Perforation and Voiding Dysfunction Rates
Exhibit 3-22: Comparative Benefits of the TVT SECUR Mini Single-Incision Sling as Compared with the MiniArc Sling System
Exhibit 3-23: The Ophira Mini Sling System
Exhibit 3-24: The Argus Adjustable Male Sling System
Exhibit 3-25: Minimally Invasive Urethral Sling Implantation, Procedure Volumes Forecast, 2010-2015
Exhibit 3-26: Minimally Invasive Urethral Sling Systems, Market Forecast, 2010-2015
Exhibit 3-27: 2010, Minimally Invasive Urethral Sling Systems Market, Share by Supplier

4. SACRAL NERVE STIMULATION

4.1 Selected Products
4.1.1 InterStim Therapy System
4.1.2 Urgent PC Neuromodulation System
4.2 Market Analysis

Exhibit 4-1: The InterStim Therapy System
Exhibit 4-2: InterStim Therapy, 12-Month and 5-Year Sustained Clinical Efficacy
Exhibit 4-3: The Sacral Plexus
Exhibit 4-4: The Urgent PC Neuromodulation System
Exhibit 4-5: Summary of a Meta-Analysis of Percutaneous Tibial Nerve Stimulation Using the Urgent PC Neuromodulation System

5. NON SURGICAL INCONTINENCE THERAPIES

5.1 Selected Products
5.1.1 Renessa System
5.1.2 NeoControl Pelvic Floor Therapy System
5.1.3 MS-106 Twin and MS-310 Pelvic Floor Stimulators
5.1.4 Liberty System
Exhibit 5-1: The Renessa System and Benefits of Treatment
Exhibit 5-2: Renessa Therapy’s Place in the Spectrum of Treatment Options
Exhibit 5-3: The Renessa Procedure and Mechanism of Action
Exhibit 5-4: NeoControl Pelvic Floor Therapy and Mechanism of Action
Exhibit 5-5: The MS-106 Twin and MS-310 Pelvic Floor Stimulators
Exhibit 5-6: Liberty System Pelvic Floor Stimulator

6. COMPANY PROFILES

6.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc.
6.2 C.R. Bard, Inc.
6.3 Boston Scientific Corporation
6.4 Caldera Medical, Inc.
6.5 Coloplast AS
6.6 Contura International AS/Idosan AS
6.7 Cook Group, Inc.
6.8 Johnson & Johnson
6.9 Medtronic, Inc.
6.10 Uroplasty, Inc.
Publisher: Medtech Insight
Перекладач: translate.google.com
Новини
03.03.2023  Науково доведено: через смартфони ви можете старіти швидше
 24.02.2023  Стимуляція спинного мозку відновлює постінсультну функцію рук
 17.02.2023  Вчені відкрили здатність жирної їжі руйнувати мозок
 10.02.2023  В Індії розробили неінвазивний тест, який використовує штучний інтелект для виявлення раку молочної залози
 01.02.2023  Як спостереження за світанками та заходами сонця впливає на здоров'я – вчені
 25.01.2023  Аналіз крові для ранньої діагностики хвороби Альцгеймера розробили вчені
 18.01.2023  Людина з серцем свині. Пацієнту вперше пересадили серце тварини
 11.01.2023  Вчені пояснили, чому оливкову олію варто пити ложками
 21.11.2022  Вчені виявили ще одну причину високого ризику атеросклерозу
 18.11.2022  Імплантована помпа доставила протиракові ліки у пухлини мозку
 16.11.2022  Шум вночі може бути причиною безсоння та серцево-судинних захворювань
 14.11.2022  ЩО ТРЕБА ЗНАТИ ПРО ЦУКРОВИЙ ДІАБЕТ: ТИПИ, СИМПТОМИ, УСКЛАДНЕННЯ
 11.11.2022  Виявилося, в епідемії ожиріння винен лише один тип їжі
 09.11.2022  Проказа: давня хвороба, здатна регенерувати органи
 07.11.2022  "Чарівні гриби" можуть лікувати важку депресію
 04.11.2022  Нове випробування пропонує переваги CV з EPA: RESPECT-EPA
 02.11.2022  Майже 500 українських медиків завершили навчання з тактичної медицини
 01.11.2022  Чи можна людям з діабетом пити алкоголь
 31.10.2022  Знайдено овоч, здатний знизити цукор у крові відразу на 20%
 28.10.2022  Людська печінка може працювати 100 років
HINARI
PubMed